| Jeffrey Ubben, ValueAct Capital |
ValueAct Capital continues to thrive despite holding onto Valeant Pharmaceuticals, the troubled drug company whose stock crashed spectacularly in the fall of 2015, and hasn’t recovered since.
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.
